Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC cut its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 15.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 170,000 shares of the company's stock after selling 30,000 shares during the period. Sivik Global Healthcare LLC's holdings in Teva Pharmaceutical Industries were worth $3,063,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. New Covenant Trust Company N.A. purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $28,000. EntryPoint Capital LLC bought a new position in shares of Teva Pharmaceutical Industries in the first quarter worth about $30,000. UMB Bank n.a. boosted its stake in shares of Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock worth $44,000 after acquiring an additional 2,067 shares during the period. Beach Investment Counsel Inc. PA purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth about $48,000. Finally, Byrne Asset Management LLC bought a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at approximately $52,000. Institutional investors own 54.05% of the company's stock.

Analyst Ratings Changes

TEVA has been the subject of several research reports. JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, October 21st. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. UBS Group lifted their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. Finally, Barclays upped their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an "overweight" rating in a research report on Wednesday, October 23rd. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $19.67.

Teva Pharmaceutical Industries Stock Down 1.1 %

Shares of TEVA traded down $0.19 during trading hours on Thursday, hitting $16.75. The company had a trading volume of 7,922,394 shares, compared to its average volume of 9,255,339. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The company has a market capitalization of $18.98 billion, a PE ratio of -19.71, a price-to-earnings-growth ratio of 1.34 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a one year low of $8.64 and a one year high of $19.31. The company's fifty day moving average price is $17.84 and its two-hundred day moving average price is $17.20.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.